Regeneron's (REGN) Next Leg Of Growth - Piper Jaffray

September 8, 2016 9:14 AM EDT
Get Alerts REGN Hot Sheet
Price: $363.24 -1.34%

Rating Summary:
    21 Buy, 17 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade REGN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Piper Jaffray analyst, Edward Tenthoff, reiterated his Neutral rating on shares of Regeneron Pharma (NASDAQ: REGN) but is looking through slowing EYLEA sales to a new leg of growth.

The analyst believes the late stage pipeline including sarilumab and dupilumab could cause an inflection point in revenue growth. The analyst stated "we anticipate approvals of sarilumab in rheumatoid arthritis (RA) by the October 30th PDUFA date and dupilumab in atopic dermatitis in 1H:17. These new product launches should re-accelerate non-GAAP diluted EPS growth from $9.16 in 2016 to $14.50 in 2017 and re-attract Big Cap growth investor interest.".

No change to the price target of $447.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $399.89 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Piper Jaffray, Edward Tenthoff, PDUFA

Add Your Comment